Skip to main content
Clinical Trials/NCT05619211
NCT05619211
Completed
Phase 1

Improving Cardiorespiratory Fitness and Cardiometabolic Health Among Children With Physical Disabilities Through Movement-to-Music Telehealth With Arm-based Sprint-Intensity Interval Training

University of Alabama at Birmingham1 site in 1 country42 target enrollmentSeptember 29, 2023
ConditionsCerebral Palsy

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Cerebral Palsy
Sponsor
University of Alabama at Birmingham
Enrollment
42
Locations
1
Primary Endpoint
Changes in pVO2
Status
Completed
Last Updated
3 months ago

Overview

Brief Summary

This study is investigating the potential effects of a high-intensity home-exercise program among children with cerebral palsy. The program includes rhythmic movements to music that are adapted for wheelchair uses and age-appropriate themes. This project has the potential to address a large knowledge gap in the extant literature, because there are no widely accessible, evidence-based, enjoyable, and age-appropriate modalities for improving cardiovascular fitness or cardiometabolic health among children with disabilities who have mobility disabilities.

Registry
clinicaltrials.gov
Start Date
September 29, 2023
End Date
December 18, 2025
Last Updated
3 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Byron Lai

Assistant Professor

University of Alabama at Birmingham

Eligibility Criteria

Inclusion Criteria

  • We are recruiting 50 parent-child dyads. Childs are the participant undergoing the exercise intervention. Parents are required to support the safety and schedule of the child participant. Parents are considered participants due to their responsibilities.
  • Inclusion Criteria:
  • have a medical diagnosis of cerebral palsy, as determined by ICD-10 codes
  • aged 6-17 years old
  • a Gross Motor Function Classification System Level I-IV (as determined via participant screening, explained in the protocol section below)
  • medical clearance to participate in high-intensity exercise from a physician (using the attached medical screening form and explained in the intervention safety, monitoring, and response plan)
  • access to a Wi-Fi Internet connection in the home via mobile phone or tablet computer
  • a caregiver who will support and monitor the participant's safety during the intervention and manage the child's exercise schedule.

Exclusion Criteria

  • physically active (defined as \>150 minutes per week of self-reported moderate-to-vigorous intensity exercise in a typical week)
  • cannot use their arms for exercise
  • a Gross Motor Function Classification Level of V
  • complete blindness or deafness;
  • Any past history of a contraindication to exercise testing according to American College of Sports Medicine (ACSM) guidelines (Liguori and American College of Sports Medicine, 2020): significant change in the resting electrocardiogram suggesting significant ischemia, myocardial infarction, or other cardiac event, unstable angina, uncontrolled cardiac dysrhythmias causing symptoms or hemodynamic compromise, symptomatic severe aortic stenosis, uncontrolled symptomatic heart failure, pulmonary embolus or pulmonary infarction, myocarditis or pericarditis, aneurysm.
  • pregnant (due to radiation from a Dual Energy X-ray Absorptiometry \[DEXA\] scan)
  • has not been seen by a physician within the last year
  • uses a g-tube
  • Eligible caregivers will include parents or legal guardians of the child, who can commit sufficient time to support the child in their roles for the study and communicate in English. Caregivers who have complete blindness or deafness will be excluded from participation.

Outcomes

Primary Outcomes

Changes in pVO2

Time Frame: Week 0, Week 13

peak oxygen consumption (mL/kg-1/min-1) obtained from a graded exercise test on an arm ergometer

Secondary Outcomes

  • changes in Hemoglobin A1C(Week 0, Week 13)
  • changes in fasting high-density lipoprotein(Week 0, Week 13)
  • changes in fasting low-density lipoprotein(Week 0, Week 13)
  • Changes in systolic blood pressure(Week 0, Week 13)
  • changes in total body fat(Week 0, Week 13)
  • changes in fat tissue percentage(Week 0, Week 13)
  • changes in fasting insulin(Week 0, Week 13)
  • changes in fasting triglycerides(Week 0, Week 13)
  • Changes in diastolic blood pressure(Week 0, Week 13)
  • change in body weight(Week 0, Week 13)
  • changes in total lean mass(Week 0, Week 13)
  • changes in C-reactive protein(Week 0, Week 13)
  • changes in lean tissue percentage(Week 0, Week 13)

Study Sites (1)

Loading locations...

Similar Trials